The Top 5 Biosimilars Articles for the Week of November 20

The Center for Biosimilars Staff

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of November 20.

Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of November 20.

Number 5: The European Medicines Agency will move to Amsterdam, Netherlands, after European ministers voted on the agency’s post-Brexit relocation.

Number 4: A recently published case study shows that a non-medical switch to biosimilar infliximab was associated with a rapid loss of treatment response in multiple patients with Behçet's disease.

Number 3: Samsung Bioepis has been granted the first European marketing authorization for a trastuzumab biosimilar, referenced on Herceptin.

Number 2: Stacie Phan, president of the Biosimilars Forum, explains the critical need for US physicians to gain better education on biosimilar therapies.

Number 1: Swiss drug maker Roche has sued biosimilar developer Pfizer over its proposed trastuzumab biosimilar.

Finally, last week, our e-newsletter asked whether you think that the so-called “nocebo” effect adequately explains patients switching away from biosimilars. To view results of the poll, visit The Center for Biosimilars® on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.